Abstract: BACKGROUND: Cogan's syndrome (CSy) is a very rare autoimmune disorder, mainly affecting the inner ear and the eye, and is associated with inflammatory bowel disease (IBD). METHODS: This was a European Crohn's and Colitis Organisation (ECCO) retrospective observational study, performed as part of the CONFER project. A call to all ECCO members was made to report concomitant CSy and inflammatory bowel disease (IBD) cases. Clinical data were recorded in a standardized questionnaire. RESULTS: This international case series reports on 22 concomitant CSy-IBD cases from 14 large medical centres. Mean duration of IBD until diagnosis of CSy was 8.7 years (range 0.0-38.0) and mean age at CSy diagnosis was 44.6 years (range 9.0-67.0). Six patients had underlying ulcerative colitis (UC) and 16 had Crohn's disease. Eleven patients (50%) had active disease at CSy diagnosis. Sixteen patients were under IBD treatment at the time of CSy diagnosis, of whom 6 (37.5%) were on anti-tumour necrosis factor (TNF). Seven out of 10 patients, who were treated for CSy with immunomodulators (mostly with corticosteroids), demonstrated at least partial response. CONCLUSION: This is the largest CSy-IBD case series so far. Although CSy is considered to be an autoimmune disease and is associated with IBD, immunomodulatory IBD maintenance treatment and even anti-TNF therapy do not seem to prevent disease onset. Moreover, IBD disease activity does not seem to trigger CSy. However, vigilance may prompt early diagnosis and directed intervention with corticosteroids at inception may potentially hinder audiovestibular deterioration. Finally, vigilance and awareness may also offer a better setting to study the pathophysiological mechanisms of this rare but debilitating phenomenon. 
Introduction
Cogan`s syndrome (CSy) is a very rare autoimmune disorder, [1] which affects the inner ear and the eyes. [2] Its typical manifestation has been first described in the 1940s. [3] The mainstay of its clinical diagnosis are audiovestibular symptoms resembling Meniere`s disease and ocular inflammation such as interstitial keratitis.
[4] In up to 70% of patients, other systemic manifestations such as arthralgia, fever or myalgias are observed with aortitis as the most complicating form. [5] Given the variable onset of symptoms, the possibility of atypical subtypes and the lack of specific laboratory tests, the diagnosis is often challenging, although cases with calcification and narrowing of the vestibular labyrinth and the cochlea on MRI have been recently described. [6, 7] Despite its very rare incidence, more than 100 cases have been published in the literature giving increasing insights into different clinical manifestations and disease pathophysiology. [8] As it is known from several autoimmune disorders, CSy shows an association with inflammatory diseases. Interestingly an assocation between CSy and inflammatory bowel diseases (IBD) such as Crohn`s disease (CD) and ulcerative colitis (UC) has been described in few patients. [7, [9] [10] [11] [12] [13] [14] [15] [16] Due to systemic manifestations in both CSy and IBD and the challenging diagnosis of CSy, diagnosing CSy in IBD patients seems to be difficult, in particular. Hitherto, a total of 13 patients with both CSy and IBD have been reported. [7, [9] [10] [11] [12] [13] [14] [15] [16] Moreover, very little is known about the underlying pathophysiological mechanism.
Herein, we report a case series of 22 patients suffering from both IBD and CSy. Given the large study population and the inclusion of patients from a total of 14 international large IBD centers, this systematic case series represents a significant contribution to the knowledge about this disease and may reveal a possible pathophysiological association between the two autoimmune-mediated diseases CSy and IBD.
MATERIALS & METHODS

Study design
This European Crohn's and Colitis Organization (ECCO) observational multicenter study retrospectively collected cases across the world through the CONFER (COllaborative Network For Exceptionally Rare case reports) project. The CONFER project was initiated by ECCO in order to specifically identify and report together rare IBD disease associations, which otherwise get seldom reported due to their exceptional rarity. Briefly, the CONFER methodology comprised of selecting a topic worthy of investigation out of case proposals submitted by ECCO members. Once a specific IBD disease association was selected by a steering committee as CONFER project (Cogan`s syndrome and IBD association in the case of the present study), ECCO launched a call to identify similar cases encountered by IBD physicians worldwide.
The call to physicians was made through announcements in the ECCO annual congress and in National IBD meetings across Europe and during several International IBD meetings. In addition, the call for similar cases was disseminated by direct emails to all ECCO members and affiliated physicians and on the ECCO website and in the ECCO eNews. Physicians were then prompted to report their case to the CONFER database using a pre-determined standardized Case Report Form (CRF). The call for the present case-series was entitled "Cogan`s syndrome in patients with IBD".
Patients and procedures
All adult IBD patients (age > 16 years) with CSy diagnosis throughout the course of IBD or prior to its diagnosis were eligible for inclusion in this study. CSy diagnosis was made based on clinical presentation according to prior case reports and reviews. [1, 17] Data were collected by a CRF, which was divided into two main sections. Section 1 included patient (epidemiological data, past medical history, alcohol consumption/smoking, family history) and disease (IBD subtype, date of diagnosis, Montreal classification, extraintestinal manifestations and IBD treatment) characteristics. Section 2 included a description of CSy with regards to diagnosis: IBD treatment at CSy diagnosis, CSy related symptoms and treatments (including cochlea implantation and treatment outcome). Relevant laboratory tests were also recorded.
Statistics
For the statistical analysis, the IBM Software SPSS Statistics Version 22.0.0 (2013 SPSS Science, Inc., Chicago, IL) was used.
RESULTS
Patients` background information
We identified a total of 22 patients from 14 medical centers across the world. 16 patients had CD and 6 patients UC. 4 of the 6 UC patients had a pancolitis (Montreal classification E3, 66.7%), while most of the CD patients showed either ileal (7 patients, 43.8%) or ileocolonic (6 patients, 37.5%) disease localisation. Mean age at enrolment was 46.6 years (range 19.0-74.0) with a mean age at IBD diagnosis of 34.7 years (range 1.0-59.0). 13 were female (59.1%), 18 patients were Caucasians (85.7%) and 2 patients (9.1%) had a positive family history for IBD with 1 patient reporting a mother with UC and two siblings with CD and another patient reporting a sister with CD. Only 3 patients (13.6%) were current smokers, 
Discussion
CSy is a very rare autoimmune disease affecting the inner ear, which may ultimately result in complete (bilateral) deafness. [18] CSy typically affects young Caucasian adults [8] with a median age of 25 years at disease onset and without gender specific predilection, [19] which is in impressive contrast to the relatively older age (median age at CSy onset of 44.6 years) and female preponderance in this case series -even if the diagnostic delay of 1 year (with a maximum of 15 years) is taken into consideration. Other autoimmune disorders occur in 15-30% of CSy patients. [2] Up to date, only 13 patients have been reported with the concomitant diagnosis of IBD and CSy. In the vast majority the onset of CSy precedes IBD manifestation. [7, 12] Herein, we report on 22 IBD patients, who were all diagnosed with CSy after IBD manifestation with a median time from IBD to CSy diagnosis of 8.7 years and a broad range of 0.0 years up to 38.0 years. Little is known about this assocation between CSy and IBD and even less is known about its pathogenetic mechanisms. Given the extremely rare incidence of CSy with not exceeding 250 cases reported in the medical literature, [18] the identification of 22 IBD patients with concomitant CSy herein may suggest a stronger association between these two entities of dysregulated immunity than previously thought.
However, as it is has been shown in several cases treated with anti-TNF for inflammatory diseases such as IBD or rheumatoid arthritis, [20] [21] [22] TNF antibodies themself may trigger neurologic symptoms, which may include CSy-like symptoms, via a demyelinating process comparable to multiple sclerosis. Nevertheless, none of the ongoing audiovestibular or other neurologic manifestations were attributed to anti-TNF in the 9 patients with prior or concomitant anti-TNF therapy.
CSy is thought to be an autoimmune disease that is mediated by a hypersensitivity response to infectious agents associated with vasculitis. [1, 23, 24] An immediate preceding upper respiratory tract infection may lead to cross-reactive auto-antibodies, in particular.
Interestingly, some case reports could show elevated titres against C. trachomatis and C.
pneumoniae. [10, 25] However, in this case series only 2 patients reported prodrome symptoms of viral infection preceding CSy diagnosis. Several antibodies directed against corneal antigens and antigens on endothelial cells and in the inner ear have been identified. [1, 16, 26, 27] One of them with reactivity against the Cogan-peptide, which shares sequence homology with CD148 and connexin 26 (expressed on endothelial cells and in the inner ear), is able to transfer the disease in animal models. [28] Moreover, histopathological examinations revealed a lymphocytic and plasma cell infiltration to the corneal and cochleal tissue suggesting a cell-mediated autoimmune reactivity. [29] This is further supported by the fact that CSy patients` lymphocytes are activated when exposed to corneal and inner ear antigens. [14, 23, 30] In contrast, IBD -with the two main subtypes CD and UC -is not regarded as a classical autoimmune disorder and its etiopathogenesis is yet incompletely understood. Nevertheless, it is considered to be a multifactorial disease, which arises from a complex interplay between genetic, environmental and immunological factors with an abnormal host immune response to environmental stimuli. [31] So far, no common pathogenetic mechanisms between CSy and IBD have been identified. To the best of our knowledge, there are no shared susceptibility genes, auto-antibodies or environmental factors. Interestingly, IBD disease activity does not seem to trigger CSy given the finding, that 50% had quiescent CD or UC at CSy diagnosis in this case series. One may assume that the association between these entities is no more than a cluster of two disorders with a dysregulated immune system rather than one common underlying autoimmune process.
Success of CSy treatment depends on its early diagnosis and early initiation of systemic corticosteroids, which are considered first line treatment in the presence of inner ear pathology, severe inflammation of the eye and/or systemic vasculitis. [17] If treatment is started within the very first two weeks after hearing loss, more than 50% of the patients show some improvement, while only 8% will improve if treatment is started later. [10, 19, 32] Combination with other immunosuppressants such as cyclosporine or methotrexate may even improve disease course. [9, 33, 34] Recently, anti-TNF treatment (with infliximab in particular) has been reported to be of some effect. [35] [36] [37] [38] However, this efficacy seems to be limited, which is consistent with our finding that 6 patients developed CSy during treatment with an anti-TNF antibody. Limited response rates of immunomodulatory treatment is also reflected in the fact that 16 patients were diagnosed with CSy despite IBD maintenance treatment. Given a relatively restrictive therapeutic approach in our 22 patients with only 10 treated with immunomodulators, treatment success rate (70% partial response) was higher than in the literature. No anti-TNF treatment was performed.
Remarkably, disease progression was observed in all other patients ultimately leading to unior even bilateral deafness in 13 of them with 4 patients requiring a cochlea implantation as ultima ratio.
However, as suggested by Scharl et al, [9] association between CSy and IBD may be even stronger than previously thought. Given the rapid progression of CSy ultimately leading to (bilateral) deafness, one should consider this very rare diagnosis in IBD patients complaining of unspecific audiovestibular symptoms such as dizziness and hearing loss and/or ocular inflammation. Although CSy is considered to be an autoimmune disease, 13 immunomodulatory IBD maintenance treatment and even anti-TNF antibodies do not seem to prevent disease onset. Moreover, IBD disease activity does not seem to trigger CSy.
However, early diagnosis is key and early initiation of systemic corticosteroids in selected patients may lead at least to a partial response and audiovestibular improvement.
Otherwise, disease progresses rapidly ultimately leading to uni-or even bilateral deafness. In conclusion, vigilance may prompt early diagnosis and directed intervention with corticosteroids at inception may potentially hinder audiovestibular deterioration. Finally, vigilance and awareness may also offer a better setting to study the pathophysiological mechanisms of this rare, but debilitating phenomena. 
